During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...

Johnson & Johnson has secured European approval for the subcutaneous formulation of Darzalex, combined with bortezomib, lenalidomide, and dexamethasone, for newly diagnosed multiple myeloma patients ...

Janssen-Cilag’s Darzalex -SC based quadruplet regimen gets European approval to treat patients with newly diagnosed MM who are transplant-eligible: Beerse, Belgium Thursday, Oct ...

Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...

The change negotiations that started on 4 September 2024 covered approximately 220 people. At the beginning of the negotiations, the planned measures were estimated to lead to the termination of up to ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the safety data from the phase 3 CEPHEUS trial in newly diagnosed multiple ...

Grandfather-of-two Bob Munro was part of the MajesTEC-2 trial to test Teclistamab and for the first time since his blood ...

Blood cancer patients in their 40s and 50s are urging Pharmac to overhaul its funding model, saying they have potentially years of work and paying tax ahead of them.

Company Announcement Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, ...

A Christchurch family are considering uprooting their lives and moving to Australia to access the blood cancer drug their mum ...